Pulmonary CT is helping pinpoint patients most likely to benefit from new minimally invasive therapies for emphysema, the fourth leading cause of death in the U.S.
Pulmonary CT is helping pinpoint patients most likely to benefit from new minimally invasive therapies for emphysema, the fourth leading cause of death in the U.S.
The pulmonary disease is "incredibly common and largely underdiagnosed," said Dr. Jeffrey Mendel, chair of radiology at Caritas St. Elizabeth's Medical Center in Boston, during a presentation at the 8th Annual International Symposium on Multidetector-Row CT in June.
Minimally invasive therapies are emerging that may allow treatment without surgery. But to make use of these therapies, optimal patient selection requires accurate assessment of the emphysema. Chest x-rays are not up to the task, and manual methods are too time-consuming and user-dependent.
Enter CT. CT morphometry is a quantitative analytic technique for measuring emphysematous changes.
"How much emphysema is there? And how much is there compared with past scans? That is where quantification helps," Mendel said.
Tabular data on CT provide total lung volume, right and left lung volume, and the ratio of emphysema volume to lung volume. Three-D visual displays offer rapid visual assessment of complex data. The images are clinician-friendly and make it easy to compare patients' global disease over time. Mendel noted that symptoms of emphysema can be improved in few ways: rehab, pharmacotherapy, and lung transplantation.
Options to improve survival include smoking cessation, use of oxygen if hypoxic and for appropriate candidates, or lung volume reduction surgery whereby the damaged bits of tissue are removed. Lung volume reduction has traditionally been achieved through open chest surgery, but researchers have recently been developing means of reducing volume with a range of minimally invasive techniques.
"We are hoping lung volume reduction via bronchoscopic methods will improve survival. This is an important goal," Mendel said.
Direct injection of an agent that causes gradual collapse of affected segments of the lung shows promise and is currently being tested in clinical trials. It's important to select the right patients for this treatment, however. Those most likely to respond have inhomogeneous emphysema, upper lobe predominance, and poor overall lung function. So far, the treatment has seen results comparable to surgery, but long-term data are required to determine if it improves survival rates, he said.
Pharmacotherapy also looks promising. Interesting research has emerged with the use of retinoic acid in shrinking emphysema and encouraging growth of normal lung, Mendel said.
"There are a lot of exciting opportunities for us to help diagnose and stratify treatment for patients subjected to the fourth leading cause of death in this country," he said. "For those of us who do pulmonary CT, this is the future. It is a very exciting time to be doing this."
For more online information, visit Diagnostic Imaging's Stanford Webcast.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.